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enzyme that converts 7-dehydrocholesterol (DHC) to choles-
terol (Chol); see Fig. 1 for selected sterols in the Chol 
biosynthesis pathway (1–8). There are nearly 200 mutations 
in DHCR7 that have been reported to date, most of them 
within a coding region of 1,425 open reading frame bases 
(9–13). Furthermore, a recent analysis of exome sequencing 
databases led to the conclusion that the carrier frequency of 
pathogenic DHCR7 mutations is 1–3% in the human popula-
tion (14). Given the number of known DHCR7 mutations, 
most SLOS cases are compound heterozygous (HET) with 
different inherited maternal and paternal alleles. The inci-
dence of clinical SLOS cases has been estimated to be 1 in 
10,000–70,000 (8). Mildly affected patients may have mini-
mal symptoms and severely affected individuals may suffer 
preterm demise, making ascertainment of clinical inci-
dence problematic (15).
While there are many studies on SLOS patients to date, 
the health status of HET DHCR7+/ mutation carriers has 
been less extensively investigated. DHCR7+/ carriers are re-
ported to have marginally higher plasma levels of 7-DHC 
than DHCR7+/+ controls (CTRs) (16) and animal studies also 
argue that a single mutant copy of Dhcr7 might affect ho-
meostasis. The 7-DHC levels are increased in Dhcr7+/ HET 
mice, with the highest levels of 7-DHC found in the ner-
vous system (17). Furthermore, the Dhcr7+/ mutant mice 
show increased dominance and elevated head-twitch re-
sponse to a challenge with a 5-HT2A agonist (18).
Circulating blood levels of 7-DHC in CTR populations 
are very low, less than 0.5 µg/ul, but recent studies have 
shown that psychiatric patients taking either aripiprazole 
(ARI) or trazodone (TRZ) have greatly increased plasma 
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levels of 7-DHC (19). In addition, a clinical report also 
noted that 15 of 22 individuals who were treated with 
either or both ARI and TRZ were misdiagnosed as SLOS 
patients based upon their 7-DHC plasma levels (20). Fur-
thermore, an unbiased cell culture study of pharmacologi-
cally  active  compounds also  identified over 5% of 700 
7-DHC-elevating compounds (21). Finally, a recent com-
prehensive review of the effect of DHCR7 inhibitors on 
human health revealed that in utero exposure to DHCR7 
inhibitors during the first trimester of pregnancy produces 
outcomes similar to those of known teratogens (22).
Exposure to DHCR7 inhibitors, such as ARI and TRZ, 
may have a significant impact on fetal health and develop-
ment, especially because their use is widespread: ARI is a 
highly prescribed drug in the US, often used during preg-
nancy. The fact that the carrier frequency of DHCR7+/ mu-
tations is high and significant exposures to drugs that affect 
this enzyme have been reported raises the question of 
whether there are groups of genetically distinct individuals 
who show increased vulnerability to exposure to DHCR7 in-
hibitors. Therefore, we monitored the response of DHCR7+/+ 
(WT) and DHCR7+/ HET fibroblasts  to  two  compounds 
that strongly inhibit the enzymatic transformation of 7-DHC 
to Chol, ARI and TRZ. Our results suggest that exposure to 
ARI and TRZ may be deleterious to individuals who are 
HET carriers of a DHCR7 mutation. We note again that ARI 
and TRZ are only two of some 35 known pharmaceuticals 
that affect levels of 7-DHC in cell culture, so the studies re-
ported here may point to a problem of broad scope.
MATERIALS AND METHODS
Materials
Unless otherwise noted, all chemicals were purchased from 
Sigma-Aldrich (St. Louis, MO). HPLC grade solvents were purchased 
from Thermo Fisher Scientific Inc. (Waltham, MA). All cell culture 
reagents were from Mediatech (Manassas, VA), Life Technologies 
(Grand Island, NY), and Greiner Bio-One GmBH (Monroe, NC). 
All sterol standards, natural and isotopically labeled, used in this 
study are available from Kerafast, Inc. (Boston MA). Delipidated 
FBS was prepared as previously described and LC-MS was used to 
confirm that it did not have a detectable Chol level (23).
CTR and DHCR7-HET fibroblast genotyping
Molecular genetic analysis of the DHCR7 gene was performed 
as previously described (10). Briefly, after amplification of exons 
3–9 (coding region) and exon/intron boundaries, bidirectional 
amplicon sequencing was performed using the BigDye Termina-
tor v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA) 
according to the manufacturer’s instructions. Samples were run 
on the ABI PRISM 310 genetic analyzer and data were analyzed 
using the Sequencing Analysis software (Applied Biosystems) (ref-
erence sequence: NM_001360.2). Sequence analysis of the DHCR7 
gene detects approximately 96% of pathogenic variants. Variant 
classification was performed according to Richards et al. (24). 
In CTR samples (CTR 1–4), exclusively benign variants were 
detected [minor allele frequency (MAF) >5%, rs1044482, 
rs1790334, rs4316537, rs949177, rs736894, rs760241, rs909217]. 
In  CTR  sample  variant  of  uncertain  significance  (VUS)-1,  a  
synonymous/silent variant (MAF <0.01, rs13972775, c1341C>T, 
p.Asp447Asp) was detected in HET form. In CTR sample VUS-2, 
a nonsynonymous variant (MAF <0.01, rs72954276, c1012G>A, 
p.Val338Met) was detected in HET form. With the evidence that 
we have, both variants were classified as a VUS.
All DHCR7+/ fibroblasts were obtained from parents of bio-
chemically  and  genetically  confirmed  SLOS  patients.  The  af-
fected patients were: a) compound HET c.[1097G>T];(964–1G>C): 
typical/classical phenotype [severity score 25 calculated ac-
cording to Kelley and Hennekam (3)]; b) compound HET c.
[1295A>G];[1328G>A]: mild (severity score 15); c) compound 
HET c.[730G>A];[976G>T]: typical/classical phenotype (severity 
score 40). In general, genotype/phenotype correlations are very 
weak in SLOS, as most of the patients are compound HET and 
there are only a low number of patients with the same genotype. 
Fig. 1. Chemical structures of selected sterols in the 
Chol biosynthesis pathway.
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Except for common mutations (60%), many are unique or in-
frequent. Patients with the same genotype can have different pheno-
types; even intra-familial variability has been observed. A detailed 
genotypic description is presented in Fig. 2. All described mutations 
are classified as pathogenic or likely pathogenic DHCR7 variants.
Cell cultures, sterol extraction and LC-MS/MS measurements, 
and statistical analyses were described in detail in previous publi-
cations and they are in the supplemental information.
RESULTS
The biosynthesis of Chol is a complex process that proceeds 
from the isoprenoid, squalene, through its epoxide to the tet-
racyclic sterol precursor, lanosterol (Lan) (25). The post-la-
nosterol biosynthetic pathway to Chol consists of two parallel 
sequences, the Bloch and Kandutsch-Russell pathways, shown 
in Fig. 1. DHCR7 is an NADPH-dependent enzyme (25) that 
reduces the 7-8 double bond of 7-DHC or the corre-
sponding Bloch pathway sterol, 7-dehydrodesmosterol. A cell 
with DHCR7 having reduced functional activity leads to ele-
vated cellular levels of 7-DHC or 7-dehydrodesmosterol and, if 
a functioning DHCR24 is present in the cell, levels of 7-DHC 
can be used as the principal biomarker to identify a compro-
mised DHCR7. Monitoring levels of 7-DHC of cells in culture 
therefore provides a straightforward method to determine 
whether DHCR7 activity is affected, either by a genetic muta-
tion or by an enzyme inhibitor (17, 26–30).
DHCR7 genetic variants
A number of different cell types have been used to assess 
the effects of small molecules on Chol biosynthesis. While 
we have successfully used Dhcr7-deficient and WT Neuro2a 
cells (17, 21, 31) in the past for screening purposes, human 
patient-derived dermal fibroblasts represent an ideal model 
for follow-up experiments (32). As a result, for the purpose 
of assessing the effect of small molecule DHCR7 inhibitors 
on a cell having only one allele bearing a DHCR7 mutation, 
we chose human fibroblasts (HFs) from six DHCR7+/ HET 
parents of a SLOS offspring and six age- and sex-matched 
donors from a CTR population. These HET fibroblast cell 
lines were HET for pathogenic or likely pathogenic DHCR7 
variants previously reported in SLOS patients. Details on 
these DHCR7+/ mutations are presented in Fig. 2. Subse-
quent to our analysis of the effect of ARI and TRZ on all 12 
CTR and HET fibroblasts, we carried out genomic analysis 
of DHCR7 of the CTR HFs as well, and in two of the six CTR 
cell lines, we identified DHCR7 VUSs. One of these variants, 
VUS#1, is a synonymous/silent codon variant that could 
potentially affect splicing (Mutation Taster, www.mutation-
taster.org; Human Splicing Finder, http://www.umd.be/
HSF3/), while the other, VUS#2 (Val338Met), is at a residue 
that is not evolutionarily conserved. Importantly, neither of 
these variants has previously been associated with SLOS. Be-
cause of the outcomes of these post hoc sequence analyses, 
the mutant-CTR comparisons of sterol biosynthesis were 
performed and are reported in six DHCR7+/ and four 
DHCR7+/+ HF lines harboring no sequence variants. Data 
for the two VUS cells with DHCR7 VUSs are reported sepa-
rately in the supplemental information.
Analysis of fibroblast sterols
Cellular  levels of endogenous sterols  in cultured fibro-
blasts were determined by methods previously reported for 
7-DHC, desmosterol (Des), Lan, and Chol (21). Measure-
ment of Chol synthesis in the presence of ARI or TRZ is 
confounded by the large amounts of pre-existing Chol that 
persist, even while Chol synthesis occurs in drug-treated 
Fig. 2. Genotyping results of HFs. Parents of children with SLOS clinical phenotypes Het-A through Het-F were gender and age matched 
with CTR fibroblasts. Mutations in Het-A through Het-F are classified as pathogenic or likely pathogenic DHCR7 variants. Genotyping of CTR 
HFs revealed two variants of unknown significance that were not previously described in SLOS clinical cases.
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fibroblasts. Nevertheless, ARI and TRZ have been shown to 
have  a  significant  effect  on  sterol  homeostasis,  as mea-
sured by absolute levels of 7-DHC and Chol, by the ratio of 
these two sterols, 7-DHC/Chol, or by the fractional Chol/
(7-DHC+Chol) determined in a cell (21).
To isolate the effect of a drug on biosynthesis, methods 
making use of isotopically labeled sterol biosynthetic pre-
cursors have been developed to measure de novo or “re-
sidual Chol synthesis” (RCS) during a treatment regimen 
(27, 33). For the ARI and TRZ studies reported here, RCS 
was assessed by the use of an isotopically labeled Lan, 
313C-Lan, bearing 13C at carbons C25, C26, and C27 of the 
sterol, which was added to fibroblasts during incubations 
with ARI or TRZ (see Fig. 3). RCS, defined in Fig. 3, re-
ports the levels of 313C-7-DHC and 313C-Chol formed dur-
ing fibroblast  exposures  to drugs.  In practice, we  report 
both the ratio of 313C-7-DHC/313C-Chol after exposure of 
fibroblasts to ARI and TRZ and the calculated RCS based 
on those isotopic sterol values. The structures of 313C-Lan, 
313C-7-DHC, and 313C-Chol are presented in Fig. 3.
Sterol levels can be measured in as few as 5,000 fibroblasts 
using the 4-phenyl-1,2,4-triazoline-3,5-dione procedures de-
scribed in the supplemental information and in previous 
publications  (21).  At  baseline,  we  found  significant  differ-
ences for sterol levels between HET and CTR fibroblasts for 
Chol, 7-DHC, and Des, while levels of 8-DHC and Lan did not 
meet the criteria for difference in these cells (see Table 1). 
Modestly elevated 7-DHC and reduced Chol levels have previ-
ously been reported in fibroblasts from obligate SLOS het-
erozygotes compared with CTR cells, but Des levels were not 
reported in those studies (16, 27).
There is a growing body of evidence suggesting that 
DHCR7 is part of a larger complex that includes another ste-
rol reductase, DHCR24 (34). It is of some interest that small 
molecules that increase levels of 7-DHC in cell culture do not 
cause a comparable increase in Des. If anything, changes in 
levels of 7-DHC and Des tend to occur in opposite directions. 
The difference is significant between DHCR7+/ fibroblasts 
and CTRs (see Table 1), but the effect of ARI and TRZ was 
not observed in fibroblasts (see supplemental information).
Human DHCR7+/ fibroblasts are preferentially affected 
by exposure to DHCR7 inhibitors
Subsequently, DHCR7+/ and CTR dermal HFs were 
treated with three different concentrations of either ARI or 
TRZ and cellular sterols were measured after 6 days in cul-
ture. Figure 4 summarizes the results for six DHCR7+/ 
HET and the four sequence-verified CTR fibroblasts. For 
all three concentrations tested, the treatments with ARI 
and TRZ resulted in significantly elevated cellular levels of 
7-DHC in both HET and CTR cells (Fig. 4A, C). ARI ap-
pears to be more potent than TRZ in increasing 7-DHC in 
both CTR and HET HFs. In addition, while 7-DHC levels 
were increased in response to both treatments, Chol levels 
were significantly decreased in the same HET and CTR fi-
broblast cultures (Fig. 4B, D). Importantly, the decrease 
in  the percentage of Chol present  in the sterol profile  is 
more pronounced in DHCR7+/ HET than in CTR fibro-
blasts (Fig. 4E, F), suggesting an increased vulnerability of 
DHCR7+/ HET to both tested compounds. Thus, ARI caused 
a decrease in the fraction of Chol present in the cells from 
nearly 1.0 (DMSO CTR) to 0.73 at 50 nM ARI, while this 
fraction dropped to only 0.85 for the CTR fibroblasts. The 
levels  of  Des  and  Lan  were  not  significantly  affected  by 
treatment and are reported in the supplemental informa-
tion. The data for all 12 of the individual cell lines (including 
the cells harboring DHCR7  variants  of  unknown  signifi-
cance) are also reported in the supplemental information.
ARI and TRZ alter de novo Chol biosynthesis
To test to determine whether ARI and TRZ act by affecting 
the stability of Chol precursors or de novo lipid biosynthesis, 
we exposed CTR and HET fibroblasts to 500 nM of 313C-Lan 
at the same time that the cells were exposed to 10, 25, and 
50 nM ARI or TRZ. This permitted assessment of the levels of 
newly synthesized Chol and its precursors by measuring the 
incorporation of isotopic label. After 6 days in culture, lipids 
were extracted and cellular levels of 313C-sterols were deter-
mined by the same methods used to analyze endogenous cel-
lular sterols, with the exception that the masses monitored in 
the LC-MS protocol were 3 m/z units higher than the natural 
m/z values for Des, 7-DHC, and Chol. Isotopically labeled ste-
rols made up approximately 10% of the total sterols present 
in the cells after 6 days of incubation. The HET and CTR cell 
lines showed a different biosynthesis profile as a function of 
ARI or TRZ concentration: for example, at 50 nM ARI, the 
ratio of 313C-7-DHC/313C-Chol found in HET cells was 3:1, 
while the same ratio was only 1.2:1 in CTR fibroblasts (see 
Fig. 5A). Indeed, the 313C-7-DHC to 313C-Chol ratio deter-
mined was  found to be significantly higher  for HET fibro-
blasts than the same ratio found in CTR cells at every 
concentration of ARI and TRZ studied.
ARI- and TRZ-induced de novo synthesized 313C-7-DHC 
and 313C-Chol depends on genotype
The drug exposure-dependent RCS is presented in Fig. 
5C, D. In the absence of drug, CTR cells synthesized Chol 
Fig. 3. Chemical structures of 3-13C-labeled sterols and the for-
mula used to calculate RCS.
TABLE 1. Sterol levels in cultured CTR and DHCR7 HET HFs
Chol 7-DHC 8-DHC Des Lan
DHCR7+/+ 59.6 ± 2.8 0.34 ± 0.08 0.81 ± 0.07 1.14 ± 0.08 0.16 ± 0.01
DHCR7+/ 48.3 ± 0.9 0.86 ± 0.08 1.03 ± 0.07 0.75 ± 0.07 0.14 ± 0.01
P 5.16E-05 4.03E-06 0.054 0.00041 0.478
Data are expressed in nanomoles per liter × 106 cells, mean ± SEM.
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more efficiently than HET cells, as evidenced by the higher 
RCS (0.97–0.98 for CTR cells and 0.93–0.95 for HET 
cells). Furthermore, the effect of ARI and TRZ on HET 
cells was larger than the effect of these drugs on CTR fibro-
blasts. Thus, on treatment with 10 nM ARI, the RCS for 
HET cells dropped to 0.65, while the RCS for CTR cells un-
der the same treatment was 0.89. At 50 nM ARI, RCS drops 
to 0.24 for HET fibroblasts, a value lower than reported for 
the RCS in some SLOS fibroblasts (33). Chol biosynthesis 
was further impaired by 100 nM ARI, but inspection of the 
cells showed evidence of toxicity at these concentrations 
and our studies were thus limited to concentrations of 50 nM 
and below. The effects of ARI on RCS were almost twice the 
magnitude of TRZ for exposure to the same drug concen-
tration, as seen by comparison of Figs. 5C and 4D.
The data for the two fibroblasts with single-copy DHCR7 
VUSs are of some interest because these mutations have 
not previously been associated with SLOS (see supplemen-
tal Fig. S1). VUS#1, a cell line with a variant that potentially 
could disrupt DHCR7 splicing (c.[1341C>T];[=]), responds 
to treatment with ARI in a manner that parallels that of 
HET cells, rather than CTR cells. However, based on the 
response to TRZ, VUS#1 is more similar to CTR cells than 
HET cells. In contrast, the VUS#2 cell line responds to treat-
ment with both ARI and TRZ like other CTR cells, suggest-
ing that this genetic variant is unlikely to be pathogenic in 
Fig. 4. Human DHCR7-HET fibroblasts are preferentially affected by exposures to DHCR7 inhibitors. Summary of 7-DHC and Chol levels 
in HF in response to various concentrations of ARI and TRZ. A, C: Graphs show average 7-DHC levels in nanograms per million cells for six 
DHCR7-HET and four CTR HFs. B, D: Graphs show average Chol levels in nanograms per million cells for six DHCR7-HET and four CTR 
HFs. E, F: Graphic representation of increasing amount of 7-DHC and decreasing amount of Chol in response to increasing amount of ARI 
(E) or TRZ (F) as measured by the ratio [Chol]/[Chol +7-DHC]. Asterisks above the bars show P values <0.01 (blue is the difference among 
CTR samples; red is the difference among HET samples; and black is the difference between CTR and HET samples. Supplemental Tables 
S1A and S1B contain companion data for Fig. 4 showing mean, SD, and SEM, as well as P values.
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the human population. This highlights our limited under-
standing of how the wide range of single-copy DHCR7 mu-
tations affect function and underscores their potential 
importance on the health of HET individuals.
DISCUSSION
The findings of our study can be summarized in several 
main points: 1) ARI and TRZ treatments significantly ele-
vate 7-DHC levels and alter the 7-DHC/Chol ratio in HFs 
regardless of genotype. 2) Response of HFs to both ARI and 
TRZ is dose-dependent. 3) DHCR7+/+ CTR and DHCR7+/ 
HET HFs respond differentially to both ARI and TRZ treat-
ments in the human therapeutic range, with HET samples 
exhibiting a stronger response with elevated 7-DHC levels 
and an altered 7-DHC/Chol ratio. Importantly, this is not a 
“higher starting point, higher end point” finding. 4) Isotope 
experiments revealed that both ARI and TRZ act through 
altering de novo biosynthesis, rather than affecting the 
stability/turnover of Chol and its precursors. The effect 
of ARI and TRZ on RCS is more pronounced for HET 
samples than on CTR cells. 5) The primary action of 
ARI and TRZ at the concentrations studied is at the step 
of 7-DHC→Chol in the biosynthesis, as the rest of the Chol 
precursor profile is unaffected by these treatments.
Our studies were performed on HFs, yet these studies 
have clear implications for brain function: the Chol biosyn-
thesis pathway is conserved across different tissue types. Al-
though the human brain only accounts for about 2% of 
total body weight, it contains as much as 25% of Chol and 
Chol derivatives (35, 36). Importantly, Chol is synthesized 
by neurons; DHCR7, the last enzyme in the Chol biosyn-
thesis pathway, is strongly expressed at high levels in neu-
rons throughout the brain (37, 38). The function of Chol 
in the CNS goes beyond being a structural component of 
cellular membranes and lipid rafts; it is required for syn-
apse and dendrite formation and axonal guidance, and 
Fig. 5.  ARI or TRZ alter residual Chol biosynthesis. Six DHCR7-HET and four CTR HFs were cultured in the presence of 500 nM 313C-Lan 
and different concentrations of ARI or TRZ. A, B: Graphs show the ratio of 313C-derived 7-DHC/313C-derived Chol; the 7-DHC is normalized 
to Chol. Asterisks above the bars show P values <0.01 (blue is the difference among CTR samples; red is the difference among HET samples; 
and black is the difference between CTR and HET samples). C, D: The calculated RCS in response to ARI or TRZ. Supplemental Tables S2A 
and S2B contain companion data for Fig. 5 showing mean, STDEV, and SEM, as well as P values.
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serves as a precursor for various biosynthetic pathways. 
Thus, the impact of ARI and TRZ on human dermal fibro-
blasts and brain tissue is likely to be very similar at a level of 
biochemistry and primarily consist of 7-DHC elevation.
It is well-established that 7-DHC elevation in cells is a 
deleterious event. The 7-DHC is a highly reactive lipid 
molecule (39) and it undergoes spontaneous free radical 
peroxidation, producing over a dozen oxidation products 
(i.e., oxysterols) in vitro and in vivo (40, 41). These 7-DHC-
derived oxysterols exert cytotoxicity, reduce cell prolif-
eration, induce premature cell differentiation, and affect 
Hedgehog signal transduction (42). They also lead to a 
host of gene expression changes that are consistent 
across the human/mouse and in vivo/in vitro models 
(40, 43, 44).
There is evidence in humans and mice that single-allele 
DHCR7 mutations lead to elevation of 7-DHC levels (17, 
27). Yet, our understanding of single copy mutations of 
DHCR7 on health remains mostly unknown to date. With 
nearly 200 different mutations in the human population 
and with a carrier rate of approximately 1–3% in the US 
(and 4% in Utah and 3% in European ancestry) (10, 22), 
their importance on health is potentially quite significant. 
A previous publication reports a correlation between birth 
weight and fetal DHCR7 gene/SNP combinations and 
Chol metabolism genes and preterm delivery (45). This 
view is also supported by animal experiments: assessment 
of behavioral differences between Dhcr7+/ HET and WT 
mice  revealed  that mutant mice  were  significantly more 
likely to win on the social dominance test and showed im-
pairments in the response to 5-HT2A agonists (18).
Developmental defects are found in 3–5% of liveborn 
children (46). It is estimated that pharmaceuticals account 
for approximately 1% of teratogenic effects (47). Our re-
sults do not necessarily indicate that ARI and TRZ are un-
safe for use in the general population. These drugs have 
been extensively tested and have proven themselves as very 
effective medications that help patients live more produc-
tive lives. ARI, marketed under the name of Abilify®, was 
the most prescribed medication in the US in 2013 (http://
www.drugs.com/stats/abilify), with 2.5 million units sold 
quarterly, exceeding yearly sales of 6.9 billion dollars. How-
ever, it is noteworthy that the Food and Drug Administra-
tion classified both ARI and TRZ as “class C” compounds, 
stating in the Risk Summary: “Adequate and well controlled 
studies with ABILIFY have not been conducted in pregnant 
women. Administer ABILIFY during pregnancy only if the 
potential  benefit  justifies  the  potential  risk  to  the  fetus.” 
(https://www.accessdata.fda.gov/drugsatfda_docs/label/ 
2014/021436s038,021713s030,021729s022,021866s023lbl.
pdf) A recent report suggested that intrauterine exposure of 
rats to ARI may not be safe for the health of developing fetuses 
and  offspring  and  that  ARI  exposure  might  significantly 
contribute to gastrointestinal congenital malformations (48). 
Human studies also highlighted the interaction between 
ARI/TRZ and Chol biosynthesis: ARI and TRZ treatment 
lead to elevated 7-DHC levels in the patient population, 
leading to a false-positive diagnosis of SLOS in patients 
treated with these two compounds (20).
It should be noted that 7-DHC elevation may not be lim-
ited to ARI and TRZ exposure. Previous screening of the Na-
tional Institutes of Health Clinical Collection, consisting of 
727 small molecules that have a history of use in human clini-
cal  trials,  identified  30  compounds  that  significantly  in-
creased 7-DHC levels in Neuro2a cells (21). Many of these 
compounds (in addition to ARI and TRZ) have been classi-
fied as class C compounds by the Food and Drug Adminis-
tration and are widely used in medicine, even during 
pregnancy. These data suggest that exposure to heterocy-
clic cationic amphiphiles, dependent on timing, duration, 
and concentration, could be harmful to the 1–3% of the 
human population who carry a single-copy of a DHCR7 
missense mutation.
In summary, our approach is directly relevant to develop-
ing personalized medicine approaches, as understanding 
pharmacogenomic interactions is essential to ensure positive 
treatment outcomes. For example, genotyping patients for 
their ability to metabolize warfarin could avoid 85,000 serious 
bleeding events, 17,000 strokes, and one billion dollars in an-
nual costs of care in the US alone (49). We argue that, in the 
era of precision medicine, potential differences in response 
to compounds that disrupt the Chol biosynthesis pathway 
must be respected, especially as their effect may be defined 
by both genetic makeup and life events at the same time. 
Thus, in the context of our studies, we suggest that treatment 
with 7-DHC-elevating substances (such as ARI and TRZ) raise 
issues for the population that carries single-allele disruptions 
of the DHCR7 gene. In addition, we propose that the vulner-
ability to 7-DHC-elevating compounds is perhaps most pro-
nounced during pregnancy and brain development, 
especially when both the mother and the fetus carry a single 
potentially disruptive DHCR7 allele. This complex drug ex-
posure × maternal genotype × fetus genotype × developmen-
tal time point interaction may elevate 7-DHC levels into a 
toxic range comparable to that seen in SLOS patients, result-
ing in deleterious developmental outcomes.
The authors thank the people who donated the biopsy samples 
used in the study, Emily Brown for assistance at the University of 
Nebraska Medical Center, and Eva Gombos and Laszlo Madar in 
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